疫苗抗原的給藥技術

疫苗抗原的給藥技術 是由出版商Datamonitor在2009年05月所出版的。 這份英文市場調查報告書包含102 pages 價格從美金3800起跳。

簡介

目錄

Abstract

Introduction

As a result of the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens, there is a need for novel antigen delivery technologies to improve vaccine efficacy and safety. This report assesses key strategies, technologies and products for vaccine antigen delivery. It provides an overview of opportunities and challenges for the sector and a future outlook.

Scope of this research

In-depth analysis of key vaccine antigen delivery technologies Thorough assessment of the potential for selected vaccine antigen delivery technologies Review of industry and academic stakeholder opinions involved in the vaccine antigen delivery sector In-depth discussion of key opportunities and risks for novel vaccine antigen delivery technologies

Research and analysis highlights

There is a significant need for novel vaccine antigen delivery technologies following the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens. Key drivers for the sector are the need for increased immunogenicity and safety as well as for vaccine formulations combining delivery systems and adjuvant.

Virus-like particles and virosomes, both benefiting from the successful track record of already marketed vaccines, have the best potential in the short- to mid term. ISCOM-based technologies could be valuable for therapeutic vaccines, while liposomes and micro-/nanoparticles will not play a major role for vaccine delivery in the foreseeable future.

Antigen stability, safety and immunogenicity are the key hurdles for novel antigen delivery technologies. In times of restricted healthcare budgets, pricing and manufacturing costs need to be kept to a minimum. The limited understanding of the detailed molecular mechanisms for many technologies poses a further challenge.

Key reasons to purchase this research

• Review profiles of key vaccine antigen delivery technologies both marketed and in clinical development and assess their future potential
• Gain insight into the current state of vaccine antigen delivery technologies and their future opportunities and challenges
• Benefit from opinions of key industry and academic stakeholders in the vaccine antigen delivery field

Table of Contents

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor insight into the vaccine delivery technologies market
• Related reports
• Upcoming related reports

ANTIGEN TYPES FOR HUMAN VACCINES

• Historic overview of antigen development for vaccines
• Live-attenuated pathogens
• Inactivated/killed pathogens
• Protein-based subunit or toxoid vaccines
• Polysaccharide subunit vaccines
• DNA/RNA vaccines

RATIONALE FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY SYSTEMS

• Novel delivery vehicles could improve the efficacy of subunit vaccines
• Improved antigen stability is a key need, particularly for mucosal administration routes
• Delivery vehicles with additional adjuvant qualities could enable the development of vaccines against challenging indications

CHALLENGES FOR THE DEVELOPMENT OF NOVEL ANTIGEN DELIVERY VEHICLES

• Cost containment could become a key hurdle for novel vaccine delivery vehicles
• More research is needed to understand the molecular mechanisms of antigen delivery
• The conservative attitude of regulators towards novel adjuvants and delivery vehicles is a key challenge
• Various new technologies are in development as antigen delivery vehicles

BACTERIAL/VIRAL VECTORS

• Summary
• General considerations
• Bacterial/viral vector vaccines in development
  • Acambis/Sanofi Pasteur - ChimeriVax technology
  • Crucell - Advax technology
  • Bavarian Nordic - MVA-BN
• Datamonitor assessment

LIPOSOMES

• Summary
• General considerations
• Liposomal vaccines in development
  • Merck Serono - Stimuvax/L-BLP25
  • NasVax - VaxiSome technology
• Datamonitor assessment

VIROSOMES

• Summary
• General considerations
• Marketed and pipeline virosomal vaccines
  • Crucell - Immunopotentiating reconstituted influenza virosome (IRIV) technology
  • Pevion Biotech - PeviPro and PeviTer virosome technologies
• Datamonitor assessment

VIRUS-LIKE PARTICLES

• Summary
• General considerations
• Marketed and pipeline VLP vaccines
  • Cytos Biotechnology - Immunodrug platform
  • Novavax - baculovirus-based VLPs
  • Others
• Datamonitor assessment

ISCOM/ISCOMATRIX

• Summary
• General considerations
• ISCOM/ISCOMATRIX-based vaccines in development
  • CSL and licensees - ISCOMATRIX
• Datamonitor assessment

MICROPARTICLES/NANOPARTICLES

• Summary
• General considerations
• Micro-/nanoparticle technologies in development for vaccines
  • PLGA - poly(-lactide co-glycolide)
  • Chitosan
• Datamonitor assessment

BIBLIOGRAPHY

• Literature

APPENDIX

• Contributing experts
  • Academic key opinion leaders
  • Industry key opinion leaders
  • Conferences
• Report methodology

TABLES

• Table: Key marketed live-attenuated vaccines, 7MM, May 2009
• Table: Summary of key antigen delivery technologies in development
• Table: Viral and bacterial vector-based vaccines for prophylactic vaccine applications, May 2009
• Table: Viral and bacterial vector-based vaccines for therapeutic vaccine applications, May 2009
• Table: SWOT analysis: bacterial/viral vector based vaccine delivery
• Table: Key pipeline liposomal vaccines
• Table: SWOT analysis - liposome-based vaccine delivery
• Table: Key marketed and pipeline virosomal vaccines
• Table: SWOT analysis - virosome-based vaccine delivery
• Table: Key marketed and pipeline virus-like particle (VLP)-based vaccines
• Table: SWOT analysis - virus-like particle (VLP)-based vaccine delivery
• Table: Key pipeline vaccines based on ISCOMATRIX
• Table: SWOT analysis - ISCOM/ISCOMATRIX-based vaccine delivery
• Table: Key micro- and nanoparticle technologies in development
• Table: SWOT analysis - microparticle-/nanoparticle-based vaccine delivery

FIGURES

• Figure: History of vaccine antigen design and delivery
• Figure: Unmet needs in antigen delivery
• Figure: Drivers and resistors for the development of antigen delivery vehicles
• Figure: Public sector immunization cost per child in the US ($), 1975 - 2008
• Figure: Vector vaccines
• Figure: Liposomal vaccine delivery
• Figure: Virosome structure
• Figure: Production of virus-like particles (VLPs)

相關商品

疫苗相關市場調查報告書

大腸癌、血管增生、癌症疫苗分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、癌症疫苗：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Cancer Vaccines
價格 : US $ 5175
出版日期 : 2012年01月

Datamonitor發行的製藥相關市場調查報告書

研究開發趨勢:心房纖維顫動患者預防中風用的抗凝血劑─即將上市的重量級新產品將留下永不消失的足跡

R&D Trends: Anticoagulants for stroke prevention in atrial fibrillation - Upcoming heavy hitters leave a permanent mark

價格 : US $ 3800

出版日期 : 2011年11月

Novartis AG:企業概要

Novartis AG: PharmaVitae Report

價格 : US $ 5700

出版日期 : 2011年11月

Novo Nordisk A/S:企業概要

Novo Nordisk A/S: PharmaVitae Profile

價格 : US $ 5700

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!